L'., R"RR Kanker
L'., R"RR Kanker
;,r"rr II
i 1 ' 1."1'_-.1,,1
PENATALAKSANAAN
KANKER PARU
Sumardi
Sub Bagian Put'nonologi Bagian ltmu Penyekil Datam Fakultes
Ked?kt:rc! U?.y/
sMF Patu RSUP tu Sardiilo
YogYakarta
61
Perlemuan llmiah Tahunan llmu Penyakt Dalam 1999
nt
N66.r or C.i. Fr rO.dD Paddion
Mcb/Fot - xld66r.,fdyBrr rit - r** zr.rrdr Lnv. - bhF d4 1,s. - r.pb.r
82
Sunardi - Penatalaksanaan Kanket Paru
Amarante-Mendes, et a/., 1998; Lamprecht didapat. Yang paling sering adalah mutasi
and Delinassios, 1998; Kalemkerian, '1994) pada onkogen. amplifikasi. transkripsi. per-
Pada kankerparu, penyebab terbanyak adalah ubahan tetak gen pada kromosom, kelainan
terjadinya perubahan gen yang berperan pada gen p53, kelainan protein p120 nukleoli
dalam apoptosis, yang disebabkan merokok iEstetler, et a/., 1999; Fontanini , et a/ . 1999;
bato, et a/., 1999; Amarante-Mendes. ef a'.
terutama sigaret. Pada sel kanker paru
terdapat lebih dari 10 kelainan genetik selyang 1998; Minna, '1998; Sirzen, et a, ' 1998)
i,/
i,r
COIlIMITMEN
Downslrea
Caspase
DNA Fragrnentatio
APOPTOSiS
63
Pertemuan llmlah Tahunan llnu Penyakit Dalam 1999
rotn'l
t"t
w,* ? p,/ 1r
,[3r
t/!e ,o rd i)
GM-CSF, lnterleukin, rhuMAb VEGF, Hyc€- al, '1998; Salomaa, efa,., 1998; Sirzen, efal,
mtin, dengan hasil sementara lebih baik dari 1998; Al-Kattan, et al, '1996).
kombinasi dengan kemoterapi kedua. Pada
masa mendatang dengan substansi biologik KESIMPULAN
ini diharapkan dapat mengontrol pertumbuhan
Di lndonesia, kanker paru pada masa
kanker, seperti mengonlrol kadar gula darah
pada penderita diabetes mellitus. Terjadi mendatang akan semakin meningkat dengan
makin banyaknya perokok. Dengan peralatan
keseimbangan antara proses apoptosis dan
anti-apoptosis.(Pinedo,'1999; Fontanini, elal,
diagnostik yang lebih baik, kemoterapi.
'1999; David, '1998; EMEAand FDA,'1998;El- radioterapi dan substansi biologik yang relatif
Deiry, 1997: Avalosse, etal, 1995). baru, diharapkan tatalaksana pasien kanker
paru akan lebih baik, terutama dalam hal
Ada beberapa faktor prognostik yang perbaikan kualitas hidupnya.
menentukan keberhasilan lerapi (complete
response/CR), antara lain tindakan pada KEPUSTAKAAN
sladium awal, kandungan DNA dan fraksi fase-
Al-Kattan, K., Sepsas, E., Townsend ER. and
S dari sel kanker, oncogen p53, Bcl-2/Bax, Founlain SW.'1996 Factors affecting longtefm
VEGF dan anemia (Shivapurkar, et al, 1999; survival following r€section for lunq cancer.
Wiyono, 1999; Giatromanolaki , ef al, '1998; Thorcx, Vol
, 1266- 1269 .
51
Lai, etal., 1998; Manegold, 1998; Muers, el Amarante-M€ndes , GP., Finucane , DM., Martin ,
SJ., Thomas G. Cotter, TG.. Salvesen, GS.
66
Sumadl - P€',lEtalal.sandan Kanl@ Pdt!
and Douglas R. Groen 1998 Anli-apoptotic Vascular ondolholial growlh facto., wild-typo
oncog€nes pr€vent caspas€_d€p€ndenl and p53, and anglog6n€sl6 ln oariy operablo noo-
indopend€nt commitment for c€ll death. Cel small cell lung cancq. Clln Cancor Res
Death and Diftercntiatlot 5,298 - 306 ;4(121t3017 -24
Avalosse, 8., Dupont, F., Burny, A. 1995 G€no Han JY, Klm HK, CholBG, Moon H, Hong YS, Lo€
lherapy for cancet. Cu ent Oplnion ln KS '1998 Quallty ot lite (OOL) asso$mont of
OnaologY 7 i94'10o. MIP (mltomycln, lfostomlde and clsplatln)
chomolhsr4y ln advanc€d non€mall c€ll lung
Brown, S., Eraul, D., Trask, C and Davison, AG' J Clln
cancors (NSCLC). JPn Oncol i
1996 Ago and the trsalmont of lung cancef.
281121i7 49-43
Ihorax, Vol 51, 564-568
Harlianto, S.H. lggg Th€ dlognostlc pot€ntl8l of
David, G. 1998 rhuMAb VEGF: antl-VEGF antlbody Nek C€ncar.
Cyft'a 21.1 ln Lung 8nd Hoad and
tr€atm€nl for Lung Cancer. UCSF CEncer
Foudh lntomatlonal Con€r"ss of 7ho As/at
conter Trl€1. NatlonalCancer lnstllulg, NIH
Cttntcdt Oncology Soclely. Augu8t I 999' Bsll.
Earle.CC. and Evans, WK 1997 Manag6msnt
Harsal, A. 1999 Mysloluppresslv€ gfroct of Pacll-
ls3ues for Stage lV Non-Small-Coll Lung
Cenc€t. Cancat Control: JMCC 4141t307 41e.
taxal - Carboplastln comblnatlon Chgmo'
Moffltt Cancor Center & Ro8€arch lnstltulg
therapy ln Non-gmall cell Lung cancs.
(NSoLC). Foslth lntematbnal Congl€st ol
El-D61ry, WS. 1997 Role ofoncogsnos ln rosls(anc€ Tho ABhn C nlcal Oncology Socrofy. AuguEt
8nd kllllno by canc€r theropsutlc agsnts ,l99€, Ball,
Cunenl Oqlnlon ln OncdqY 9t79'47.
Hsrse B, oallchau H, Wormann B, H€mm6ddn B,
Esteller M, Senohez-Cospedes M, Ro8sll R' Schmldb€Qor H, Hoss cF, Hannomann P,
Sldraneky D, Baylln SB, Herman JG i999 Crl6o CP, Hlddlmann W, Grloslnger F i998
o6t6ctlon of aberrant promotor hyp.r- lnductlon comblnallon chemolhorspy wlth
msthylatlon of tumor Eupprosaor gon68 ln
doc€taxol and ca&opl6lln ln advgno6d non'
a€rum ONA from non-8mall coll lung cancar
patlente, CarcarReq 59(l ):67-70
sm€ll-cbll lung Qahcor. /horac catdlovasc
Su€i48(5):298-302
Euroooan Mqdlclno3 Ev€luatlon Aogncy and FDAs
Hka3hlma T, Tskada M, Komva T, Nltls T, Malarhl
Oncologlc Drugs Advlsory Commllleo 1998
K, Masuds N, Matul K, Klkul M, Yalumltsu T,
Hyc8min Approved ln Swltzorland for Small
K6w63e I i998 Proonostlc slgnlflc6nco of
CellLung Canc€r. US FDABulletin Soptsmb€r
1S98.
oYFM 21-i ln non-rmall c€ll lung oancor'
An cancer Res 18(88)147,13-6
FontenlnlG, Boldrlnl L, calclnalA, Chlns S' Lucchl
M, Mussl A, Ang€lgttl CA Basolo F, Bovllacqua
Jusuf, A. lggg Experlonc€ ot Trookn6nt of Luno
G '1999 ThrombospondlnB land llmesBengor Cancor p!tl6nt! uslng Paclltaxel and
RNA oxPr€88lon ln lung carclnoma: Carboplatln. Foudh,nlema onal Congrcst ol
rslstionBhlp wllh p53 altoretlons, snglogonlc me Aslan c nlcal oncobgy socrely' Augult
'1999, Ball.
growth fEctor8, 9nd va8cular dsn8lty C//n
bancatRes; 5(1)r'155-61 Jeremlc B, shlbamoto Y, Mlllclc B, Nlkollc N,
Fonlanln{G, BoldrlnlL, Chlneg, Plseturo F, Basolo Dagovlc A, Mlllsavlj€vlc S 1998 concunenl
F,CalclnalA, LucchlM, MusslA, Angglg$ CA' radlochomolherapy lor patlgnts wlth alsgs lll
Bgvllaoqua G 1999 Expro$lon of va6cular non-small-coll lung cancer (NSCLC): long'
endothellal growth factor mRNA ln non-8mall- term rosulls of a phas€ ll gludy. lnt J Rcdraf
cell lung qarclnomes Sa J Caroor;79(2)13€3- Oncol glol Physi 42(51:1091,.8
I Kurie,JM.,L€e,Js.,Morlc€,Rc.,Wal8h,GL,,Khurl,
clskomanolakl A, Koukourakls Ml, Kakolyrls S' FR., Broxson,A., Ro, JY., Fr€nklln,WA., Ren
Turl€y H, O'Byme K, Scott PA, Pezzolla F, Yu, Hong, WK. lggE Aulofluorsecanco
Georgoullas V, Harrls AL, Gatler KC 1998 Bronchoscopy ln ths Dot€ctlon of aquamous
67
--
Melaplsgla snd Dysplasls ln Currenl snd tttumstlonal Congrcss ot The Asidn Clinicel
Formor Smokers J Nal, Crtc€r,tsl Vol 90, Onco,ory Socbfy. August 1 999, Bsll.
No. l3: S91-1006. NCI/FDO Physlclan Sialomonl 1998 Non'small coll
Kalemkerlan, GP. 19s4 Blology of lung cancer' lung canc€r - Updstod l2l98 : Stage lV non-
Cuftenl Oplnbn ln Oncdogy 6:147'156' lmall coll luno cancer. 6dltors@oncolink
I uo€nn.6du
Komlya T. Hlrsshlma T, Kawase 1999 Cllnlcal
glonlllcanco of p53 ln non-small cell lung Nlkllnlkl J, Butzykowskl T, Nlkllnska W, Laudanski
cancq. Oncol ReP',8(11',19'28 J, Chycze$/skl L, Rapellino M, Furman M 1998
LaiCL, T3€lCM, ToalTT, Kuo Bl, Chang KT, Fu HT' Prooporsllvo CYFRA 2l-1 l6vel as a
Perng RP, Chon JY 1998 Prcsoncs of lorum prognostb lndicalof ln rs8eclsd nm"6mall coll
€nii-ps3 ontlbodlss ls assoclatod with pl€ural lung canc.r, Eur Respi? J;'12(6):1424-8
offuslon and poor prognoll3 ln lung cancor Noftsmall Coll Lung Csnc€r Collobo.alivE Group
pall€ntr. C,r, C€aca. Ros;4( 12):302t3o i995 Chomoth6rapy ln non'small osll lung
canoer: nrela-anglpls uslng updale dala on
I
Lamprocht, SA snd O€llnas8los, JD. 'l 998 Apopbsls
ln cr6.c6. Cal Death dttd Dfftercntblbn 6: lndlgdual patl€nts from 52 randomls€d ollnlcsl
337 i 339 hl8l8. BMJ : 3'l1: 8S0-909
Manegold, C. 1998 The causss and pro9noltlc Psvlcovlc R, Mlllclc J, Bubanovlc G, Sup€ S '1998
sldnlficanca ol lol{ hemoglobln lovelr ln tumor Sgrum tuftor mark€r CYFRA 21-l ln lho
p;tbnlr. Slrrhtonthet onftot 174 Suppl4:17- dlalnostlcs ot Non-small Call lung cance.
I Co AdDpo422(2)r629.35
M6r0ono, 8. l Ogg Palllatlvs chomolh6..py ln Non' Pln€do, H,M. 19S0 The Promls€ snd Challenge ot
Small Coll Bronchoggnlc CarclnomE. Fout t ths Comblnatlon of Chemolh6rapy and
tntema onat Congi6,ss ot The Athn Clnlc,d Blologlcsl Agents. Foudh lntenationdl
Orcobgy Soclely August 'l 999' Ball. Congtqts ot lha rsran C nicol Oncology
Socroly. August f909, Ball.
Mhna. JD. lggg N6opl63m ot lho Lung ,n A.S.
Faucl, E. Braunwald, K.J. lslolbach€r, J.D.- Porzo C, Gnvlns A, Rufido P, Cbf,l R, Marcstlll P,
Wlson, J,B. Martln, o.L. Kalpet, S.L Hsu!6r D6ll€ Vlttorla M, Monlardlnl S, Comella G,
and O.L. Longo (€&): Hantsottb P,ncrpbs ot FralclG, Comolls P, Panza N, Do Cataldls G,
Mod,c/no 14b Edltlon, pp 55268 Mccraw'Hlll Dcl Gelzo F. 1998 Carboplatln-or8l otoposldo
lntemallonal Edltlons, Now Yo* p8rloisllsad doslng ln oldorly non-small csll
lung oancff pEtl6nt9. Gruppo Oncologlco
NtcKonna, WG., Mlcha€l McKonna, M.' gnd Jos€ph Eu
Trest, J. 1998 UPCC 6594 A pha.e ll Non'
Cooporatlvo Sud-ltalla J
Crtc6ti34( ):1
I 'l 7'10-4
Randomlzed, Opsn-Lobol, Multlple'Do8€
olth!
Str/dy As3€sllng the Eficacy snd Safoty Rs€d, JC '1999 DysrEgulatlon ol Apoptosls in
of R€dlothorspy plus lnuavgnously Cancor. J C n Otco, 17:2941'2953'
AdmlnElerod Tlrspazamlno tn Subjoc't8 wlth
Sslollrla, ER,, Lllppo, K., Taylor, P , Palmgren' J.,
Stag€ lllB Non-Small Csll Lun0 Canosr. Halp6koskl, Vlrtamo, J and l"lqlnonon, OP.
Unlv€rllty ot Ponnsylvanla Cancor Conllr l9e8 Prognoslt of Patlenl8 wlth Lung csncer
€dltor6doncollnk.up€nn-€dtl
Found ln a Slngle Chest Radlogtaph
Muers. MF,, Shevlln, P.nd Brown, J. 1996 Scr6€nlng. Ctest1'l4(6): 1514''l518
Progno6ls h lung cancor; phyglcl6m'oplnlons
Salo, G., Sslo, Y., Uchlyams, B , Kunano, N ,
comp€rrd wlth ouloomo and a prsdlctlvc Sugawrr|, S., Fujlmu.a, S. , Sato, M '
model, Tro.ax, Vol 61,894-!02
Saga ra, M., Ohkuda, K , Kolk€, K , Mln€ml,
Nakagawr, K, 1909 Cunsnt st3tur ol tho h66tnont Y,, Satoh, K. 6nd Nuklws, T. I 999 Prognostlc
for Advancod Lung Cancat ln Japan Foutllt Value ol Nucleolar Protsln p120 ln Pstlonts
68
Sumardi - Penatalaksanaan Kanket PaN
Wilh Resected Lung Adenocaacinoma. J Clln apoptotic index in small cell compared with
Oncol 17:2721-2727. non-small cell lung carcinoma cell linss; lack
of correlation with Bcl-2lBax. Lung Cancea
Satoh H, Ohara K, Fuji H, lshikawa H, Yamashita
22(11:1-13
YT, Kamma H, Ohtsuka M, Hasegawa S 1998
Use of daily low-dose carboplatin in Sridhar KS. Lobo CF. Altman RD 1998 Digilalclubb-
radiolherapy for non-small cell lung canc€r. ing and lung cancer. Chosf; 114(6):1535-7
A n ti c a n ce r Re s ;1 8(68). 4625 -7
Sheard, D. and Gosney, JR. 1996 Endocrine cells Sutandyo, N. 1999 Chemolherapy of Non-SmallCell
in tumour-bearing lungs. Thorax,Vol Sl ,721- Lung Cancor at the Dharmais Cancer Center
726. Hospital, Jakarta, lndonesia. Foutlh lntematio-
nal Congr9ss of The Asian Clinical Oncology
shepherd, FA. 1995 lntralhoEclc complications of Socbfy. August 1999, Bali.
mallgnancyand ils tre€tfie . Curent Opinion
Trotti, A. '1997 Toxkrity antagonists in cancertherapy.
in Oncology 71150-157 .
Cuffenl Opinion ln Oncorogy 9:569-578.
Shivapurkar N, Vlrmani AK, Wistuba ll, Milchgrub
Wlyono, w.H. i999 Prognostic factor of DNA
S, ft,,lackay B, Minna JD, Gazd€r AF 1999
contont and S-phago fraction in Operable Non-
Deletions of chromosom€ 4 at multlple slles
small Cell Lung cancer: Preliminary report.
ar6 froquenl in mallgnant mesotholloma and
Foutlh htemational Congross of The Asian
small cell lung carclnoma. CIin Cdncet Clinical Oncology Sociefy. August 1999, Bali.
Ros;s(1):17-23
Wodd Hoallh Orgarrlzation. 1995 National Cancer
Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Control Programmes I Policies and Managerial
Lewensohn R 1998 Higher spontaneous Guidelines. WHo. Geneva.
69